ClinicalTrials.gov
ClinicalTrials.gov Menu

Transitioning From Cyclosporine to Alefacept in Psoriasis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00143806
Recruitment Status : Completed
First Posted : September 2, 2005
Last Update Posted : January 5, 2009
Sponsor:
Collaborator:
Biogen
Information provided by:
Rutgers, The State University of New Jersey

Brief Summary:
The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept.

Condition or disease Intervention/treatment Phase
Psoriasis Drug: Transitioning patients from cyclosporine to alefacept Phase 2

Detailed Description:
The purpose of this study is to devise a safe and effective method for transitioning patients from cyclosporine to alefacept. Patients in the study are well controlled on cyclosporine and desire to switch to alefacept. The study is done in three phases. In Phase 1 (12 week duration) the two drugs will be overlapped, with cyclosporine slowly tapering. Both drugs will be discontinued after 12 weeks. In Phase 2 (12 weeks duration), patients are off both drugs. In Phase 3 (24 weeks long), patients are on a second course of alefacept alone for 12 weeks and then off for 12 weeks. Topical and UV light treatments are allowed throughout the study. Total length of study is one year.

Study Type : Interventional  (Clinical Trial)
Enrollment : 13 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Investigator-Initiated, Use Study of Alefacept (Amevive) in Combination With Tapering Doses of Cyclosporine in Patients With Moderate to Severe Psoriasis
Study Start Date : October 2003
Study Completion Date : May 2007

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Psoriasis
U.S. FDA Resources




Primary Outcome Measures :
  1. Static physicians global assessment (PGA) and quality of life as measured by DLQI


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years to 80 Years   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria

  • Adult psoriasis patients (18 to 80 years old), who are well controlled on cyclosporine (Static PGA score of mild, minimal or clear) and who need or desire to stop cyclosporine and start alefacept.

Exclusion Criteria

  • CD4 <400
  • Active infection (other than trivial URI, etc.)
  • History of AIDS or Hepatitis B, C
  • Inability to understand consent or comply with study requirements
  • Pregnancy or Lactation
  • History of heart or liver disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00143806


Locations
United States, New Jersey
UMDNJ Clinical Research Center
New Brunswick, New Jersey, United States, 08903
Sponsors and Collaborators
University of Medicine and Dentistry of New Jersey
Biogen
Investigators
Principal Investigator: Alice Gottlieb, MD, PhD Rutgers, The State University of New Jersey

ClinicalTrials.gov Identifier: NCT00143806     History of Changes
Other Study ID Numbers: 4513
First Posted: September 2, 2005    Key Record Dates
Last Update Posted: January 5, 2009
Last Verified: December 2008

Keywords provided by Rutgers, The State University of New Jersey:
psoriasis
cyclosporine
transition
alefacept

Additional relevant MeSH terms:
Psoriasis
Skin Diseases, Papulosquamous
Skin Diseases
Cyclosporins
Cyclosporine
Alefacept
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Immunosuppressive Agents
Immunologic Factors
Physiological Effects of Drugs
Antifungal Agents
Anti-Infective Agents
Dermatologic Agents
Antirheumatic Agents
Calcineurin Inhibitors